Updates in Advanced Renal Cell Carcinoma from The 2022 International Kidney Cancer Symposium - Episode 1

Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)

December 15, 2022

Hans Hammers, MD, PhD, Moshe Ornstein, MD

Hans Hammers, MD, PhD, describes how patients with advanced renal cell carcinoma are risk-stratified, and the go-to treatment approach for intermediate risk patients.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

Now Viewing

EP. 1: Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)

EP. 2: Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC

EP. 3: Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC

EP. 4: Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment

EP. 5: Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial

EP. 6: Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment

EP. 7: COSMIC-313: Frontline Triplet Therapy in Advanced RCC

EP. 8: Emerging Data in Non-Clear Cell RCC Treatment

EP. 9: Exciting Investigational Therapies in Advanced RCC